DE60116758T2 - Einkapselung eines toxischen kerns in einen nicht-toxischen bereich in einer oralen darreichungsform - Google Patents

Einkapselung eines toxischen kerns in einen nicht-toxischen bereich in einer oralen darreichungsform Download PDF

Info

Publication number
DE60116758T2
DE60116758T2 DE60116758T DE60116758T DE60116758T2 DE 60116758 T2 DE60116758 T2 DE 60116758T2 DE 60116758 T DE60116758 T DE 60116758T DE 60116758 T DE60116758 T DE 60116758T DE 60116758 T2 DE60116758 T2 DE 60116758T2
Authority
DE
Germany
Prior art keywords
region
toxic
liquid
dosage form
potent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60116758T
Other languages
German (de)
English (en)
Other versions
DE60116758D1 (de
Inventor
C. Francis Somerville PAYUMO
Chen-Chao West Windsor WANG
K. Jill Edison SHERWOOD
J. Michael Winchester CIMA
M. Christopher Princeton Junction GAYLO
C. Donald Rednor MONKHOUSE
Jaedeok West Orange YOO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Therics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology, Therics Inc filed Critical Massachusetts Institute of Technology
Publication of DE60116758D1 publication Critical patent/DE60116758D1/de
Application granted granted Critical
Publication of DE60116758T2 publication Critical patent/DE60116758T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y10/00—Processes of additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y70/00—Materials specially adapted for additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00—Products made by additive manufacturing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60116758T 2000-05-18 2001-05-18 Einkapselung eines toxischen kerns in einen nicht-toxischen bereich in einer oralen darreichungsform Expired - Lifetime DE60116758T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20589600P 2000-05-18 2000-05-18
US205896P 2000-05-18
PCT/US2001/040763 WO2001087272A2 (en) 2000-05-18 2001-05-18 Encapsulating a toxic core within a non-toxic region in an oral dosage form

Publications (2)

Publication Number Publication Date
DE60116758D1 DE60116758D1 (de) 2006-04-06
DE60116758T2 true DE60116758T2 (de) 2006-11-02

Family

ID=22764098

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60116758T Expired - Lifetime DE60116758T2 (de) 2000-05-18 2001-05-18 Einkapselung eines toxischen kerns in einen nicht-toxischen bereich in einer oralen darreichungsform

Country Status (9)

Country Link
US (2) US7276252B2 (https=)
EP (1) EP1286663B1 (https=)
JP (2) JP5178982B2 (https=)
AT (1) ATE315930T1 (https=)
AU (1) AU2001263506A1 (https=)
CA (1) CA2408956C (https=)
DE (1) DE60116758T2 (https=)
ES (1) ES2257412T3 (https=)
WO (1) WO2001087272A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9155871B2 (en) 2010-11-19 2015-10-13 C. Miethke Gmbh & Co Kg Electrically operable, in one possible embodiment programmable hydrocephalus valve

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6518330B2 (en) * 2001-02-13 2003-02-11 Board Of Trustees Of University Of Illinois Multifunctional autonomically healing composite material
EP1439824A2 (en) * 2001-10-29 2004-07-28 Therics, Inc. Three-dimensional suspension printing of dosage forms
WO2003037244A2 (en) * 2001-10-29 2003-05-08 Therics, Inc. System for manufacturing controlled release dosage forms, such as a zero-order release profile dosage form manufactured by three-dimensional printing
CA2464478C (en) * 2001-10-29 2012-03-20 Therics, Inc. A system and method for uniaxial compression of an article, such as a three-dimensionally printed dosage form
DE60323482D1 (de) * 2002-05-06 2008-10-23 Massachusetts Inst Technology Diffusionskontrollierte arzneiform sowie herstellungsmethode mittels dreidimensionalem drucken
AU2004258953B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004258949B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2535177A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
US8062672B2 (en) * 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
AU2004270170B2 (en) * 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2538064C (en) * 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US20050087902A1 (en) * 2003-10-28 2005-04-28 Isaac Farr Alginate-based materials, methods of application thereof, and systems for using the alginate-based materials
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
US7566747B2 (en) * 2004-05-07 2009-07-28 The Board Of Trustees Of The University Of Illinois Wax particles for protection of activators, and multifunctional autonomically healing composite materials
TWI428271B (zh) * 2004-06-09 2014-03-01 Smithkline Beecham Corp 生產藥物之裝置及方法
US20060002594A1 (en) * 2004-06-09 2006-01-05 Clarke Allan J Method for producing a pharmaceutical product
JPWO2006004069A1 (ja) * 2004-07-01 2008-04-24 日本碍子株式会社 微小カプセルおよびその製造方法
CA2572292A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
EP1827391B1 (en) * 2004-11-26 2015-09-23 Aprecia Pharmaceuticals Co. Three dimensionally printed dosage forms
US7829000B2 (en) * 2005-02-25 2010-11-09 Hewlett-Packard Development Company, L.P. Core-shell solid freeform fabrication
US7612152B2 (en) * 2005-05-06 2009-11-03 The Board Of Trustees Of The University Of Illinois Self-healing polymers
US7914776B2 (en) * 2005-10-07 2011-03-29 Adolor Corporation Solid dispersions of opioid antagonists
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
WO2007082153A2 (en) * 2006-01-05 2007-07-19 The Board Of Trustees Of The University Of Illinois Self-healing coating system
GB0608402D0 (en) * 2006-04-28 2006-06-07 Diurnal Ltd Thyroid treatment
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US7569625B2 (en) * 2006-06-02 2009-08-04 The Board Of Trustees Of The University Of Illinois Self-healing elastomer system
US8299015B2 (en) 2006-07-25 2012-10-30 Lipoxen Technologies Limited Derivatisation of granulocyte colony-stimulating factor
US20080107725A1 (en) * 2006-10-13 2008-05-08 Albano Antonio A Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
US20080299391A1 (en) * 2007-05-31 2008-12-04 White Scott R Capsules, methods for making capsules, and self-healing composites including the same
WO2009007969A2 (en) * 2007-07-09 2009-01-15 Colint Ltd. Portable hydration apparatus
US20090181254A1 (en) * 2008-01-15 2009-07-16 The Board Of Trustees Of The University Of Illinois Multi-capsule system and its use for encapsulating active agents
JP2011074015A (ja) * 2009-09-30 2011-04-14 Tomita Pharmaceutical Co Ltd 固形製剤及びその製造方法
MX353289B (es) * 2011-05-25 2018-01-05 Taiho Pharmaceutical Co Ltd Tableta revestida en seco que contiene tegafur, gimeracil y oteracil potasico.
US9381154B2 (en) * 2011-06-09 2016-07-05 Xerox Corporation Direct inkjet fabrication of drug delivery devices
US8414654B1 (en) * 2011-11-23 2013-04-09 Amendia, Inc. Bone implants and method of manufacture
CN102551927A (zh) * 2011-11-29 2012-07-11 上海大学 嵌入式分级释药三维支架及其制备方法
US8888480B2 (en) 2012-09-05 2014-11-18 Aprecia Pharmaceuticals Company Three-dimensional printing system and equipment assembly
DK2892708T3 (en) 2012-09-05 2019-01-28 Aprecia Pharmaceuticals LLC THREE-DIMENSIONAL PRESSURE SYSTEM AND EQUIPMENT
US20140099351A1 (en) 2012-10-04 2014-04-10 Axxia Pharmaceuticals, Llc Process for making controlled release medical implant products
JP6466399B2 (ja) 2013-03-15 2019-02-06 アプレシア・ファーマスーティカルズ・カンパニー トピラマートの急速分散性の剤形
CA2906029C (en) 2013-03-15 2017-09-05 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
CA2906107C (en) * 2013-03-15 2021-08-24 Aprecia Pharmaceuticals Company Rapidly dispersible dosage form of oxcarbazepine
EP3033188A4 (en) 2013-08-16 2017-03-22 The Exone Company Three-dimensional printed metal-casting molds and methods for making the same
US20160243621A1 (en) 2013-10-17 2016-08-25 The Exone Company Three-Dimensional Printed Hot Isostatic Pressing Containers and Processes for Making Same
US11001048B2 (en) 2013-12-23 2021-05-11 The Exone Company Method of three-dimensional printing using a multi-component build powder
US20160332373A1 (en) 2013-12-23 2016-11-17 The Exone Company Methods and Systems for Three-Dimensional Printing Utilizing Multiple Binder Fluids
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
EP3148730A1 (en) 2014-05-29 2017-04-05 The Exone Company Process for making nickel-based superalloy articles by three-dimensional printing
EP3169499A2 (en) 2014-07-17 2017-05-24 The Exone Company Methods and apparatuses for curing three-dimensional printed articles
US9854828B2 (en) 2014-09-29 2018-01-02 William Langeland Method, system and apparatus for creating 3D-printed edible objects
EP3227109B1 (en) 2014-12-03 2020-08-19 The Exone Company Process for making densified carbon articles by three dimensional printing
AU2016272089B2 (en) 2015-06-03 2021-02-18 Triastek, Inc. Dosage forms and use thereof
JP6903659B2 (ja) 2015-08-21 2021-07-14 アプレシア・ファーマスーティカルズ・エルエルシー ３次元プリントシステムおよび装置アセンブリ
US11576859B2 (en) 2015-10-23 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
WO2017100367A1 (en) 2015-12-08 2017-06-15 Lyndra, Inc. Geometric configurations for gastric residence systems
JP6878417B2 (ja) * 2016-02-17 2021-05-26 トリアステック インコーポレイテッド 剤形およびそれらの使用
AU2017261372B2 (en) 2016-05-05 2019-02-14 Triastek, Inc. Controlled release dosage form
CN109310639A (zh) 2016-05-27 2019-02-05 林德拉有限公司 用于胃驻留系统的材料结构
US10765658B2 (en) 2016-06-22 2020-09-08 Mastix LLC Oral compositions delivering therapeutically effective amounts of cannabinoids
GB201612853D0 (en) * 2016-07-25 2016-09-07 Univ Central Lancashire Solid dosage form production
JP2019532947A (ja) 2016-09-30 2019-11-14 リンドラ，インコーポレイティド アダマンタン系薬物の持続的送達のための胃内滞留システム
GB201620066D0 (en) 2016-11-28 2017-01-11 Ucl Business Plc Solid Pharmaceutical dosage formulations and processes
EP3573602A4 (en) 2017-01-26 2020-09-16 Triastek, Inc. DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES
US11602502B2 (en) 2017-02-24 2023-03-14 Hewlett-Packard Development Company, L.P. Three-dimensional (3D) printing a pharmaceutical tablet
GR1009361B (el) 2017-05-11 2018-09-17 Κωνσταντινος Ηλια Θεοδοσοπουλος Συστημα παραγωγης μεσω τρισδιαστατης εκτυπωσης, δισκιων, κοκκιων και καψουλων
JP7358340B2 (ja) 2017-05-26 2023-10-10 インフィニット・マテリアル・ソリューションズ，エルエルシー 水溶性ポリマー組成物
CA3066658A1 (en) 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
CN116270513A (zh) 2018-01-09 2023-06-23 南京三迭纪医药科技有限公司 一种包含固定剂量adhd非兴奋剂和adhd兴奋剂的复方口服药物剂型
US10350822B1 (en) 2018-01-09 2019-07-16 Triastek Inc. Dosage forms with desired release profiles and methods of designing and making thereof
DE102018107585B3 (de) * 2018-03-29 2019-03-28 Universität Rostock Vorrichtung zur Herstellung von 3D-gedruckten Wirkstofffreisetzungssystemen mit Wirkstoffdepots, sowie Verfahren zur Herstellung von 3D-gedruckten Wirkstofffreisetzungssystemen
IT201800004265A1 (it) 2018-04-06 2019-10-06 Apparato e metodo per la produzione automatizzata di forme di dosaggio personalizzabili.
JP7614103B2 (ja) 2018-10-15 2025-01-15 アプレシア・ファーマスーティカルズ・エルエルシー 包装内に剤形を形成する方法およびシステム
WO2020143864A1 (de) * 2019-01-07 2020-07-16 Nuuvera Deutschland GmbH Vorrichtung für die tablettierung einer pulverförmigen, flüssigen, pastösen, verkapselten oder granularen wirkstoffzusammensetzung
US11724486B2 (en) 2019-07-09 2023-08-15 Kyndryl, Inc. Printing customized medication based on current user data and medical records of the user
GB201913972D0 (en) 2019-09-27 2019-11-13 Univ Ulster Pharmaceutical Delivery Device and method of manufacture
US12371581B2 (en) 2020-03-25 2025-07-29 Infinite Material Solutions, Llc High performance water soluble polymer compositions
JP2023533478A (ja) 2020-06-26 2023-08-03 アプレシア・ファーマスーティカルズ・エルエルシー 内部空洞を有する迅速口内分散可能な錠剤
EP4238556A4 (en) 2020-10-30 2024-09-25 Triastek, Inc. GASTRORETENTIVE PHARMACEUTICAL DOSAGE FORM
US12251208B2 (en) 2020-11-30 2025-03-18 International Business Machines Corporation Time controlled medication
GB2608846A (en) * 2021-07-14 2023-01-18 Quay Pharmaceuticals Ltd Method and apparatus for additive manufacturing

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2801203A (en) * 1951-03-22 1957-07-30 Byk Gulden Lomberg Chem Fab X-ray method of digestive enzyme diagnosis using protected core of contrast agent
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5082669A (en) 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
US5215989A (en) 1989-12-08 1993-06-01 Merck & Co., Inc. Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
US5314696A (en) * 1991-06-27 1994-05-24 Paulos Manley A Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor
AU5592694A (en) * 1992-11-05 1994-05-24 Merck & Co., Inc. Drug delivery device
US6280771B1 (en) * 1997-02-20 2001-08-28 Therics, Inc. Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof
ZA949929B (en) * 1993-12-23 1995-08-23 Akzo Nobel Nv Sugar-coated pharmaceutical dosage unit.
JPH07223970A (ja) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤
ES2188657T3 (es) * 1994-04-22 2003-07-01 Yamanouchi Pharma Co Ltd Sistema para la liberacion especifica en el colon de un farmaco.
US5597829A (en) * 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
WO1998036739A1 (en) 1997-02-20 1998-08-27 Therics, Inc. Dosage forms exhibiting multiphasic release kinetics and methods of manufacture thereof
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6294199B1 (en) * 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9155871B2 (en) 2010-11-19 2015-10-13 C. Miethke Gmbh & Co Kg Electrically operable, in one possible embodiment programmable hydrocephalus valve

Also Published As

Publication number Publication date
ES2257412T3 (es) 2006-08-01
DE60116758D1 (de) 2006-04-06
US7276252B2 (en) 2007-10-02
CA2408956A1 (en) 2001-11-22
WO2001087272A2 (en) 2001-11-22
EP1286663B1 (en) 2006-01-18
WO2001087272A3 (en) 2002-04-18
US7875290B2 (en) 2011-01-25
US20060110443A1 (en) 2006-05-25
AU2001263506A1 (en) 2001-11-26
EP1286663A2 (en) 2003-03-05
JP5178982B2 (ja) 2013-04-10
JP2012082224A (ja) 2012-04-26
US20020015728A1 (en) 2002-02-07
ATE315930T1 (de) 2006-02-15
JP2003533470A (ja) 2003-11-11
CA2408956C (en) 2011-07-12

Similar Documents

Publication Publication Date Title
DE60116758T2 (de) Einkapselung eines toxischen kerns in einen nicht-toxischen bereich in einer oralen darreichungsform
DE69434640T2 (de) Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe
DE69431089T2 (de) Formulierungen mit kontrollierter Abgabe überzogen mit wässrigen Dispersionen von Ethylcellulose
DE60212475T2 (de) Pharmazeutische Tablette und ein Verfahren zu ihrer Herstellung
DE69817010T2 (de) Spheroide, verfahren zu ihrer herstellung und diese enthaltende arzneiformen
DE60312333T2 (de) Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung
DE69631981T2 (de) Lansoprazolhaltige Arzneizusammensetzung und Herstellungsverfahren
DE69231415T2 (de) Stabilisiertes Substrat für kontrollierte Freigabe mit von einer wässerigen Dispersion eines hydrophobischen Polymers abgeleitete Beschichtung
AU652945B2 (en) Bioceramic system for delivery of bioactive compounds
DE102004012273B4 (de) Stabile und geschmacksmaskierte pharmazeutische Dosierungsform unter Verwendung von porösen Apatit-Körnern
DE60020343T2 (de) Cilostazol enthaltende zubereitung
DE60208673T2 (de) Umhüllte pellets auf basis eines ace-hemmers
DE69828527T2 (de) Polyethylenglycol-matrixpellets für fettige, ölige oder klebrige arzneistoffe
EP0771189A1 (de) Formulierung zur inhalativen applikation
DE10250088A1 (de) Gegen Missbrauch gesicherte Darreichungsform
EP0551820A1 (de) Geschmacksmaskierte pharmazeutische Mittel
JP2789525B2 (ja) 調節放出性物品
DE602005003343T2 (de) Arzneiimittel mit verdecktem geschmack in aufbrechenden multipartikeln
DE602005006409T2 (de) Ein amin-arzneimittel enthaltende granulatzubereitung mit langsamer freisetzung auf basis von teilchen mit einer überzugsschicht und entsprechendes herstellungsverfahren
EP3713543A2 (de) Taschenförmige oral auflösende filme mit hoher wirkstoffbeladung
DE69934781T2 (de) Morphinsulfat enthaltende mikrogranulate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen
DE69904465T2 (de) Therapie von depressionen
Thombre et al. In vitro/in vivo correlations of sustained-release coated multiparticulate formulations of doxazosin
DE19940794A1 (de) Pharmazeutische Zubereitung
DE29824797U1 (de) Magensaftresistent überzogene Arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, CAMBRID, US